hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06329726 id: NeuroPsico_DBS&PD briefTitle: Long-Term Behavioral and Cognitive Outcomes of Deep Brain Stimulation in Patients With Parkinson's Disease overallStatus: RECRUITING date: 2021-12-13 date: 2031-12-15 date: 2032-12-15 date: 2024-03-26 date: 2024-03-26 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: The goal of this observational study is to evaluate the long-term effect of DBS-STN on cognitive and behavioral outcomes in Parkinson's disease (PD) patients.
Researchers will compare data collected from patients with DBS versus patients with best medical therapy. conditions: Parkinson Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 52 type: ESTIMATED name: Clinical examinations and clinical scales administration measure: Long-term characterization of DBS-STN on cognitive outcomes measure: Beck Depression Inventory measure: State-Trait Anxiety Inventory measure: Questionnaire for Impulsive-Compulsive Disorders in Parkinson measure: Pittsburgh Sleep Quality Index measure: Parkinson's Disease Questionnaire-8 measure: Minnesota Multiphasic Personality Inventory 2-RF sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico status: RECRUITING city: Milan state: Lombardia zip: 20135 country: Italy name: Eleonora Zirone, Dr role: CONTACT phone: 0255038671 phoneExt: 0039 email: eleonora.zirone@policlinico.mi.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06329713 id: 2024-03/11 briefTitle: Effect of Auto-Bolus Interval on Analgesic Quality During Labor Analgesia With Dural Puncture Epidural overallStatus: RECRUITING date: 2024-03-15 date: 2025-03-01 date: 2025-08-01 date: 2024-03-26 date: 2024-04-02 name: Ataturk University class: OTHER briefSummary: It is aimed in this study to compare the effect of changing the interval time for programmed auto boluses of local anaesthetics on the total anesthetic consumption and quality of labor analgesia with dural puncture epidural technique. conditions: Analgesia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Group I: 30 Min Interval Time name: Group II: 60 Min Interval Time measure: Difference between total local anaesthetic consumption sex: FEMALE minimumAge: 25 Years maximumAge: 45 Years stdAges: ADULT facility: Atatürk University status: RECRUITING city: Erzurum country: Turkey name: Ayşenur Dostbil role: CONTACT phone: +905333677796 email: adostbil@hotmail.com lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06329700 id: ParSparInLivAtrophy briefTitle: Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy overallStatus: COMPLETED date: 2010-05-01 date: 2019-12-31 date: 2022-06-30 date: 2024-03-26 date: 2024-03-26 name: Azienda Ospedaliero Universitaria Maggiore della Carita class: OTHER briefSummary: Major hepatectomy in patients with colorectal liver metastases (CLM) and post-chemotherapy liver atrophy is associated with increased complications. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. The aim of this study was to assess the clinical impact of post-chemotherapy liver atrophy on patients undergoing PSH for CLM. For this purpose, the occurrence of liver atrophy was recorded and then computed against the occurrence of postoperative morbidity and mortality. conditions: Colorectal Cancer Stage IV studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 74 type: ACTUAL name: Hepatectomy measure: Postoperative complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06329687 id: OPP-010 briefTitle: A Study Evaluating the Safety of the Nasal Pump overallStatus: TERMINATED date: 2024-02-21 date: 2024-02-28 date: 2024-02-28 date: 2024-03-26 date: 2024-04-18 name: Oyster Point Pharma, Inc. class: INDUSTRY briefSummary: The objective of this study is to determine the safety of the Tyrvaya nasal pump. conditions: Dry Eye conditions: Kerato Conjunctivitis Sicca studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 5 type: ACTUAL name: Tyrvaya Nasal Pump measure: Incidence of Adverse Events measure: Tear Film Break up Time measure: Eye Dryness Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: United States, California city: Newport Beach state: California zip: 92663 country: United States lat: 33.61891 lon: -117.92895 hasResults: False
nctId: NCT06329674 id: 20DM30203 briefTitle: Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients overallStatus: COMPLETED date: 2021-04-27 date: 2022-12-01 date: 2023-06-13 date: 2024-03-26 date: 2024-03-26 name: AJU Pharm Co., Ltd. class: INDUSTRY briefSummary: A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase 3 study to evaluate the efficacy and safety of the combination of A51R3 and AJU-A51 compared with the combination of A51R3 and A51R2 in patients with Type 2 diabetes mellitus who have inadequate glycemic control with the combination of A51R3 and A51R2 conditions: Type2 Diabetes studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 235 type: ACTUAL name: AJU-A51 name: A51R2 name: A51R3 name: AJU-A51 Placebo name: A51R2 Placebo measure: Changes in HbA1c sex: ALL minimumAge: 19 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Asan Medical Center city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06329661 id: CYS-007 briefTitle: A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-11-30 date: 2025-12-31 date: 2024-03-26 date: 2024-03-28 name: Novaliq GmbH class: INDUSTRY briefSummary: The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED) conditions: Dry Eye Disease studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 200 type: ESTIMATED name: Cyclosporine ophthalmic solution, 0.1% (VEVYE) name: Saline solution, 0.6% measure: Change from baseline in corneal ECD sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06329648 id: DECIDE briefTitle: Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer acronym: DECIDE overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-12-31 date: 2028-06-01 date: 2024-03-26 date: 2024-03-26 name: The Netherlands Cancer Institute class: OTHER briefSummary: Cardiac dose was not a major concern in lung radiotherapy patients until the results of the RTOG (Radiation Therapy Oncology Group) 0617 trial, which showed an association between cardiac dose and survival. Since then, many papers have studied the association between cardiac (substructure) dose and either survival or cardiac toxicity. Ideally, cardiac toxicity would be separated from survival. However, scoring cardiac toxicity prospectively was not standard practice, and retrospective scoring is challenging because of the overlap of cardiac toxicity symptoms and lung cancer (treatment) symptoms. Therefore in real world cohorts, cardiac toxicity is usually not scored properly and most larger studies pragmatically consider overall survival as primary endpoint, and the relation between cardiac dose and cardiac toxicity is not well established for lung cancer patients.
Cardiac toxicity might not be the only factor in decreased survival; toxicity of the immune system might be a competing risk or a major contributing factor, where dose to the heart is a surrogate for dose to blood. Dose to the immune system is defined as EDIC (Effective Dose to circulating Immune Cells), comprising heart dose, lung dose and body dose combined. As EDIC dose and cardiac dose partly overlap, a large cohort with substantial variation will be required to disentangle the two effects. Such vast amounts of routine care data are immediately available in many radiotherapy centers all over the world. The problem we face is not the lack of routine care data, but making such data available for analysis. DECIDE adopts a federated learning approach, which implies that data does not have to be centralized within a single institution to be fit for use. We aim to include an unprecedentedly large-scale cohort of 20,000 patients.
In this proposal, we need to add on scientific and technological innovations that exploit the existing federated learning framework to scale up to supporting \>25 simultaneously connected partners. We will be training (generalized) linear epidemiological models as well as new computer vision-based models for outcome predictions. As cause-specific survival (cardiac toxicity or immune toxicity) is unavailable or unreliable in major studies, we will use the more pragmatic endpoint of survival. By elucidating the clinical contributions of whole heart dose, cardiac substructure dose and EDIC dose in combination with known clinical risk factors, the desired impact is to change clinical practice for lung cancer radiotherapy and improve survival. conditions: NSCLC studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 20000 type: ESTIMATED measure: Optimize EDIC dose measure: cardiac toxicity sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06329635 id: 2023070K briefTitle: Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-03-26 date: 2024-03-26 name: The Affiliated Hospital Of Guizhou Medical University class: OTHER briefSummary: To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage. conditions: Aneurysmal Subarachnoid Hemorrhage conditions: Vasospasm studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: The assigned "intervention" will be performed only by a separate unblinded dedicated physician who signs the confidential agreement. The attending/investigating physician and patient are blinded to the intervention assignment. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 396 type: ESTIMATED name: Intrathecal Nicardipine name: No intervention measure: Dichotomized Modified Rankin Scale (mRS) 0-2 vs 3-6 measure: Extended Glasgow Outcome Score (GOS-E). measure: Modified Rankin Scale ordinal shift with mRS 5 and 6 combined measure: Dichotomized Modified Rankin Scale (mRS) 0-3 vs 4-6 measure: Hamilton Depression Rating Scale (HAM-D) score measure: Hamilton Anxiety Rating Scale (HAM-A) score measure: Mini-Mental State Examination (MMSE) score measure: Montreal Cognitive Assessment (MoCA) scale score measure: Change of National Institutes of Health Stroke Scale (NIHSS) score measure: Cerebrospinal fluid shunt surgery rate measure: Overall mortality rate measure: Rate of CSF infection measure: Rate of any type of new intracranial hemorrhage. measure: Adverse Event measure: Serious Adverse Event sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06329622 id: KY2023-972 briefTitle: Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-06-30 date: 2026-06-30 date: 2024-03-26 date: 2024-04-17 name: Huashan Hospital class: OTHER briefSummary: The investigators hypothesize that Ketosteril can improve sarcopenia in patients with renal disease without increasing the burden on the kidneys and causing deterioration of renal function. Therefore, this study intends to take patients with CKD stage 3-4 and sarcopenia as the research object, give Ketosteril intervention or not to patients on the base of low-protein diet, and clarify the clinical benefits of Ketosteril prescription for improving sarcopenia in patients with CKD. conditions: Chronic Kidney Disease conditions: Sarcopenia studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 58 type: ESTIMATED name: low-protein diet + Ketosteril name: low-protein diet measure: skeletal muscle mass index (SMI) measure: changes in eGFR(ml/min/1.73m2) measure: serum albumin(g/l) measure: grip strength(kg) measure: BMI(kg/m2) measure: 6m walking speed(s) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Nephrology, Huashan hospital city: Shanghai zip: 200040 country: China name: Mengjing Wang role: CONTACT phone: +8613764676029 email: fiyona27@126.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06329609 id: ClA-333 briefTitle: Airvo 3 Respiratory Rate Validation Study overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2024-10 date: 2024-03-26 date: 2024-03-26 name: Fisher and Paykel Healthcare class: INDUSTRY briefSummary: This is a clinical performance testing to validate the accuracy of the Airvo 3 device with respiratory rate algorithm manufactured by Fisher \& Paykel Healthcare for continuous respiratory rate monitoring. conditions: COPD conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ESTIMATED name: Airvo 3 with respiratory rate algorithm measure: Respiratory rate measure: Respiratory rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Element Boulder city: Louisville state: Colorado zip: 80027 country: United States name: Monica Rabanal, MSc, BSN role: CONTACT email: monica.rabanal@element.com name: Blair Holman, MS role: CONTACT phone: +1 651 379 5549 email: Blair.Holman@element.com name: Monica Rabanal, MSc, BSN role: PRINCIPAL_INVESTIGATOR lat: 39.97776 lon: -105.13193 hasResults: False
nctId: NCT06329596 id: H-55146 id: D43TW012274 type: NIH link: https://reporter.nih.gov/quickSearch/D43TW012274 briefTitle: Microbiome Alterations With Xylitol (MAX) in Pregnancy acronym: MAX overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-03-31 date: 2026-03-31 date: 2024-03-26 date: 2024-04-19 name: Baylor College of Medicine class: OTHER name: Fogarty International Center of the National Institute of Health name: University of Washington name: Baylor College of Medicine Children's Foundation Malawi briefSummary: The purpose of this study is to understand if chewing xylitol-gum initiated before 20 weeks of pregnancy and continued until delivery affects the bacteria that are found in the oral and vaginal cavities, signs of inflammation within the gingiva of the oral cavity, the health of the tissues in the mouth (clinical parameters of periodontal disease), and the bacteria in the mouth and gut of newborns among pregnant individuals in Malawi. conditions: Dysbiosis conditions: Inflammation Gum studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: TRIPLE maskingDescription: Participants, data collectors (i.e. dental officers, study staff members, clinical officers), and data analysts will be blinded (triple-blinded) to group allocation throughout the study. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Xylitol gum name: Sorbitol gum measure: Periodontal disease at 28-30 weeks of pregnancy measure: Periodontal disease at 6 weeks postpartum measure: Alterations in the maternal oral microbiome communities delivery measure: Alterations in the maternal vaginal microbiome communities measure: Inflammatory mediator changes in the maternal gingival crevicular fluid at measure: Alterations within the infants' oral microbiome communities measure: Alterations within the infants' gut microbiome communities sex: FEMALE minimumAge: 12 Years maximumAge: 60 Years stdAges: CHILD stdAges: ADULT facility: Area 25 Health Center city: Lilongwe country: Malawi name: Benjamin Shayo role: CONTACT phone: +265980888996 email: benjamin.shayo@bcm.edu lat: -13.96692 lon: 33.78725 hasResults: False
nctId: NCT06329583 id: 23-012635 briefTitle: Establishing Pressures at the EGJ During Diaphragmatic Breathing Using High-resolution Esophageal Manometry overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-26 date: 2024-03-26 name: Mayo Clinic class: OTHER briefSummary: The goal of this study is to determine which position, maneuvers or combination thereof generates the highest pressure at the EGJ as assessed by high-resolution esophageal manometry and thus greater or more robust contraction of the diaphragm. conditions: Gastroesophageal Reflux conditions: Dysphagia conditions: Esophageal Motility Disorders studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ESTIMATED name: diaphragmatic breathing measure: Pressure at the esophagogastric junction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06329570 id: NF-2023-03 briefTitle: Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-12-31 date: 2027-03-31 date: 2024-03-26 date: 2024-03-26 name: NaviFUS Corporation class: INDUSTRY name: NaviFUS US LLC briefSummary: This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide. conditions: Glioblastoma Multiforme conditions: Glioblastoma conditions: Glioma conditions: Brain Tumor conditions: Neoplasms conditions: Neoplasms, Nerve Tissue studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: NaviFUS System name: Lumason name: Bevacizumab measure: Adverse Events (AEs) measure: 6-month Progression-Free Survival (PFS-6) measure: Progression-Free Survival (PFS) measure: One-year Survival Rate measure: Overall Survival (OS) measure: Objective Response Rate (ORR) measure: Clinical Benefit Rate (CBR) measure: Local Disease Control on the MRI Images measure: Corticosteroid Consumption measure: Quality of life (QoL) assessment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Virginia city: Charlottesville state: Virginia zip: 22903 country: United States name: Jason Sheehan, M.D., Ph.D. role: CONTACT phone: 434-924-8129 email: JPS2F@uvahealth.org name: Arthur Lung, Ph.D. role: CONTACT phone: 02-25860560 phoneExt: 180 email: arthur.lung@navifus.com lat: 38.02931 lon: -78.47668 hasResults: False
nctId: NCT06329557 id: 23-007188 briefTitle: Optimizing the Patient Experience Through Provider Coaching or Communication Intervention overallStatus: ENROLLING_BY_INVITATION date: 2024-03-08 date: 2025-02 date: 2026-02 date: 2024-03-26 date: 2024-04-19 name: Mayo Clinic class: OTHER briefSummary: Hypothesis: Clinicians who receive patient experience coaching or communication classes have improved patient satisfaction scores and improved clinician satisfaction. conditions: Patient Satisfaction conditions: Communication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 45 type: ESTIMATED name: Intervention 1 measure: To identify if patient experience coaching or communication classes have an effect on patient satisfaction scores and clinician satisfaction. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 facility: Mayo Clinic city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06329544 id: STUDY-23-01572 id: 1R01DK137968-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01DK137968-01 briefTitle: High Fructose Diet, the Gut Microbiome, and Metabolic Health overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-02 date: 2028-11 date: 2024-03-26 date: 2024-03-26 name: Icahn School of Medicine at Mount Sinai class: OTHER name: Metabolic Solutions Inc. name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: Americans commonly consume excess amounts of dietary fructose. Added fructose has been shown to have an adverse impact on metabolic health, including increased insulin resistance and type 2 diabetes (T2D) risk. However, the mechanisms that link dietary fructose and metabolic health are poorly understood. Malabsorption or incomplete metabolism of fructose in the small intestine is common in the population. Excess fructose reaches the colon where it may change the structure and function of the gut microbiome, alter bacterial metabolites and trigger inflammatory responses impacting T2D risk. To elucidate whether commonly consumed levels of dietary fructose influence metabolic outcomes through altering the gut microbiome, the research team will randomize 30 participants to a controlled cross-over dietary intervention, in which the participants will consume 12-day isocaloric, added fructose or glucose diets (25% of total calories) separated by a 10-day controlled diet washout period.
The research team will measure 1) microbiota community structure and function via metagenomic sequencing of stool, 2) fecal metabolites via targeted and untargeted metabolomics, 3) anthropometrics, 4) insulin resistance, serum markers of T2D risk and inflammatory cytokines, 5) fecal microbial carbohydrate oxidation capacity and 6) liver fat via MRI elastography. The research team will use novel statistical approaches, including Distributed Lag Modeling, to understand the complex relationships between diet, the microbiome, metabolites and health outcomes.